The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
On April 10, 2025, Dexcom announced it had received FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring system for use in adults aged 18 and older. The system extends wear time to ...
DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results